-
10:30
-10:50
*Risk of COVID-19 infection in patients with inflammatory bowel disease
-
10:50
-11:10
*Quality of care for patients with IBD during COVID-19 pandemic
-
11:10
-11:30
*COVID-19 vaccination safety, intent and perceptions in inflammatory bowel diseases
-
11:30
-11:45
(BA03) Risankizumab therapy induces improvements in endoscopic endpoints in patients with moderate-to-severe Crohn’s disease: results from two phase 3 studies
-
11:45
-12:00
*(BA04) Effect of ustekinumab maintenance on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn's disease (CD) through 48-weeks: STARDUST trial
COVID-19 Forum COVID-19: experience is the record of mistakes
